CUSTOpharm, Inc.

CUSTOpharm, Inc.

CUSTOpharm, Inc.

Date Founded



2325 Camino Vida Roble,CARLSBAD, CA 92011

Type of Company


Employees (Worldwide)

11 - 50


Hospitals & Patient Services
Medical Support Services
Advertising & Marketing

Company Description

CUSTOpharm, Inc. provides personalized chemistry and regulatory support services. It provides personalized cost-effective chemistry and manufacturing controls (CMC) and regulatory support to companies with limited resources and those seeking to expand into new areas. The firm offers product development services that focus on non-clinical, clinical, marketing, and other aspects of drug development and distribution; sourcing of product manufacturing with specialization in injectable dosage forms, including suspensions, lyophilized, and cytotoxic compounds, technology transfer, regulatory support, such as electronic submissions, electronic hybrids, paper applications/CTD/traditional format, structured product labeling. The company was founded by David McCleary in 2005 and is headquartered in San Diego, CA.

Executives & Employees

Chief Executive Officer


Chief Financial Officer

Board of Directors

Operating Partner at Water Street Healthcare Partners LLC

Partner at Water Street Healthcare Partners LLC

Paths to CUSTOpharm, Inc.
Potential Connections via
Relationship Science
CUSTOpharm, Inc.
Recent Transactions
Details Hidden

CUSTOpharm, Inc. purchases Aspire eCTD LLC

Details Hidden

Water Street Healthcare Partners focuses exclusively on investments in the healthcare sector. The firm invests in middle-market companies and lower-priority divisions of global companies in the following areas: diagnostic devices, medical products, pharmaceutical services, specialty distribution, specialty pharmaceuticals and specialty services. Water Street does not invest in biotechnology, traditional healthcare facilities such as hospitals or nursing homes or in early-stage companies without positive cash flow. They firm looks for companies with: (1) a leading market share (2) established brands and/or strong customer relationships (3) strong sales and distribution capabilities (4) platforms with the potential for expansion into new products, services and technologies and (5) management teams interested in retaining an ownership stake. Investments typically range from $50 million to $500 million.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by CUSTOpharm, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of CUSTOpharm, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and CUSTOpharm, Inc..